You are here: Industry Insights > Fruquintinib

News List

Domestic New Drug R&D Strength is Gradually Ascending, and Overseas Product Authorization is in Full Swing WND/PharmaSources
December 14, 2023
On November 13th, LEGN.US reached an 1 billion US dollar cooperation agreement with Novartis Pharmaceuticals.
Overseas Marketing of Fruquintinib Accelerated as It Receives the FDA’s Fast Track Designation PharmaSources/Xiaoyaowan
July 06, 2020
Hutchison MediPharma’s targeted anticancer drug: fruquintinib has recently received the Fast Track designation granted by the FDA for the treatment of patients with metastatic colorectal cancer (mCRC).
Chi-Med, BeiGene Enter Clinical Collaboration contractpharma
May 27, 2020
Will evaluate combinations of surufatinib and fruquintinib with tislelizumab for multiple solid tumor cancer indications.
Chi-Med announces commercial launch of Elunate biospectrumasia
November 28, 2018
Elunate is for the treatment of patients with metastatic colorectal cancer (CRC) that have been previously treated with fluoropyrimidine, oxaliplatin and irinotecan.
Finally! The 100% Chinese-produced Targeted Anti-cancer Drug Fruquintinib Developed by Hutchison MediPharma for 13 Years to be Marketed Caicai
September 07, 2018
The blockbuster targeted anti-cancer drug Fruquintinib that I’ve been following has finally achieved new significant progress recently.
Rise! Chinese-produced Drug! Fruquintinib Opens Up a New Direction for the Treatment of Advanced Colorectal Cancer Ye Fenghong
July 24, 2018
Colorectal cancer is one of the common malignancies, with morbidity and mortality gradually rising worldwide.